STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring StemCells Inc. (Nasdaq:STEM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/STEM

StemCells Inc. (STEM) is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell; and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.

Message Board Search for STEM: http://www.boardcentral.com/boards/STEM

In the report, the analyst notes:

"For the first quarter of 2010, the Company reported a net loss of $6,124,000, or $(0.05) per share, compared with a net loss of $9,281,000, or $(0.10) per share, for the first quarter of 2009. Total revenue was $230,000, a 307% increase over total revenue of $57,000 for the same period of 2009.

"STEM recently announced that it has submitted a protocol to the FDA for initiation of a second clinical trial of its proprietary HuCNS-SC^(R) human neural stem cells in neuronal ceroid lipofuscinosis (NCL), which is also often referred to as Batten disease. NCL is a genetic disorder characterized by the absence of a critical enzyme, which leads to the loss of neurons and the eventual death of the patient. The Company completed a phase I clinical trial in NCL in January 2009 and reported the results to the FDA in September 2009."